These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Survey draws attention to HYDROmorphone knowledge deficits. Alta RN; 2012; 68(3):12-3. PubMed ID: 23162986 [No Abstract] [Full Text] [Related]
8. [Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study]. Junker U; Figge V MMW Fortschr Med; 2005 Oct; 147 Suppl 3():91-6. PubMed ID: 16261943 [TBL] [Abstract][Full Text] [Related]
9. Controlled-release opioids and alcohol. Darke AC CMAJ; 2006 Jan; 174(3):352. PubMed ID: 16446485 [No Abstract] [Full Text] [Related]
10. Stability and tolerability of high concentrations of intrathecal bupivacaine and opioid mixtures in chronic noncancer pain: an open-label pilot study. Goucke CR; Dusci LJ; Van Leeuwen S; Fairclough D; Ilett KF Pain Med; 2010 Nov; 11(11):1612-8. PubMed ID: 21029352 [TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial comparing the safety and efficacy of a hydromorphone titration protocol to usual care in the management of adult emergency department patients with acute severe pain. Chang AK; Bijur PE; Gallagher EJ Ann Emerg Med; 2011 Oct; 58(4):352-9. PubMed ID: 21507527 [TBL] [Abstract][Full Text] [Related]
12. Effects of an opioid taper algorithm in hematopoietic progenitor cell transplant recipients. Parran L; Pederson C Oncol Nurs Forum; 2002; 29(1):41-50. PubMed ID: 11817492 [TBL] [Abstract][Full Text] [Related]
13. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials. Grosset AB; Roberts MS; Woodson ME; Shi M; Swanton RE; Reder RF; Buckley BJ J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867 [TBL] [Abstract][Full Text] [Related]
15. Opioid withdrawal syndrome on switching from hydromorphone to alfentanil. McMunnigall F; Welsh J Palliat Med; 2008 Mar; 22(2):191-2. PubMed ID: 18372384 [TBL] [Abstract][Full Text] [Related]
16. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain. Wallace M; Thipphawong J Pain Med; 2010 Oct; 11(10):1477-88. PubMed ID: 21199302 [TBL] [Abstract][Full Text] [Related]
17. [Pain therapy with semisynthetic opioids. Patients have opioid-type side effects more rarely]. Sohn W MMW Fortschr Med; 2003 Jul; 145(27-28):50. PubMed ID: 14587190 [No Abstract] [Full Text] [Related]
18. FDA asks Purdue Pharma to withdraw Palladone. FDA Consum; 2005; 39(5):7. PubMed ID: 16419284 [No Abstract] [Full Text] [Related]
19. Intrathecal hydromorphone added to hyperbaric bupivacaine for postoperative pain relief after knee arthroscopic surgery: a prospective, randomised, controlled trial. Lee YS; Park YC; Kim JH; Kim WY; Yoon SZ; Moon MG; Min TJ Eur J Anaesthesiol; 2012 Jan; 29(1):17-21. PubMed ID: 21562420 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial. Chang AK; Bijur PE; Baccelieri A; Gallagher EJ Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]